Basit öğe kaydını göster

dc.contributor.authorÖzdemir, İsa Aykut
dc.contributor.authorÖncül, Mustafa Oral
dc.contributor.authorAbatay Sel, Figen
dc.contributor.authorKuruca, Dürdane Serap
dc.contributor.authorOğuz, Fatma
dc.contributor.authorSüleymanoğlu, Mediha
dc.contributor.authorErol, Ayşe
dc.date.accessioned2021-12-10T10:33:49Z
dc.date.available2021-12-10T10:33:49Z
dc.identifier.citationSüleymanoğlu M., Erol A., Abatay Sel F., Özdemir İ. A. , Oğuz F., Kuruca D. S. , Öncül M. O. , "Inhibitory Effect of Wharton Jelly Derived Mesenchymal Stem Cells on Chronic Myeloid Cancer Cell Lines", 6th European Congress of Immunology, İstanbul, Türkiye, 1 - 04 Eylül 2021, ss.252
dc.identifier.otherav_47817002-e893-4117-b9f0-a9aa1a834930
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/170142
dc.identifier.urihttps://doi.org/10.1002/eji.202170200
dc.description.abstractMesenchymal stem cells (MSCs) have the capacity for self‐renewal and pluripotency, making them a primary candidate for cell‐based therapy. The purpose of this study was toevaluate inhibition effect of Wharton Jelly derived MSC (WJ‐MSC) on the K562 cells as chronic myeloid leukemia (CML) cell lines. In this study, WJ‐MSCs were isolated from an umbilicalcord, and characterized by flow cytometry. WJ‐MSCs (1×104/cm2) were obtained from Passage 1, and plated into 24‐well plates in 1 ml DMEM complete culture medium solution.WJ‐MSCs were incubated in a flask at 37˚C in a humidified air with 5% CO2. After 7 hours, K562 cells (1×105/ml) were added respectively K562: MSC; 1:2, 1:5, 1:10 ratio, low‐glucoseDMEM containing 10% FBS and 1% penicillin/streptomycin solution. The co‐culture was incubated 72 hours at 37˚C in 5% CO2, and the co‐cultured K562 cells were subsequentlyseparated from adherent WJ‐MSCs by slow and careful pipetting. The cell counts and viability were determined by trypan blue dye exclusion. The viable and non‐viable cells werecounted with a hemocytometer. The non‐viable cell percentages were compared as 1:2 (42%), 1:5 (52,2%), 1:10 (33,3%) and control plates (%7,69) (untreated K562 cell line) after 72hours incubation. The most effective dose was found 1:5 (52,2%). In conclusion, the results showed that WJ‐MSCs can suppress K562 cell proliferation when using in proper ratio. Thisstudy will provide perspective on the next projects. In the future, WJ‐MSCs may be an option for their clinic use for the inhibition of cancer cells.Keywords: Cancer immunology, cellular interactions, stem cells
dc.language.isoeng
dc.subjectHealth Sciences
dc.subjectInternal Medicine
dc.subjectAssessment and Diagnosis
dc.subjectMedicine (miscellaneous)
dc.subjectGeneral Medicine
dc.subjectKlinik Tıp (MED)
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectKlinik Tıp
dc.subjectBiyoloji ve Biyokimya
dc.subjectTIP, GENEL & İÇECEK
dc.subjectBİYOLOJİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectTıbbi Biyoloji
dc.subjectFamily Practice
dc.subjectFundamentals and Skills
dc.subjectGeneral Health Professions
dc.subjectPathophysiology
dc.titleInhibitory Effect of Wharton Jelly Derived Mesenchymal Stem Cells on Chronic Myeloid Cancer Cell Lines
dc.typeBildiri
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Temel Tıp Bilimleri Bölümü
dc.contributor.firstauthorID2721011


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster